Drug treatments in people with intellectual disability and challenging behavior: Time to rethink?

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Tyrer, Peter ^a   Cooper, Sally Ann ^b   Hassiotis, Angela ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; SEDATIVE AGENT; TRANQUILIZER;

BEHAVIOR DISORDER; CHALLENGING BEHAVIOR; COHORT ANALYSIS; DETERIORATION; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; INTELLECTUAL IMPAIRMENT; MEDICAL EDUCATION; METABOLIC SYNDROME X; MORTALITY; NERVOUSNESS; OBESITY; PHARMACEUTICAL CARE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SECONDARY HEALTH CARE; TREATMENT INDICATION;

AGGRESSION; ANTIPSYCHOTIC AGENTS; HUMANS; INTELLECTUAL DISABILITY; MENTAL DISORDERS;

EID: 84903975869     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4323     Document Type: Editorial

References (12)

1. Cooper S- A, Smiley E, Morrison J, Allan L, Williamson A. Prevalence of and associations with mental ill-health in adults with intellectual disabilities. Br J Psychiatry 2007;190:27-35. (Pubitemid 46121498)
2. Doan TN, Lennox NG, Taylor-Gomez M, Ware RS. Medication use among Australian adults with intellectual disability in primary healthcare settings: A cross-sectional study. J Intellect Dev Disabil 2013;38:177-81.
3. Ghosh S, Arulrajan AE, Baldwin D. Unlicensed applications of licensed psychotropic drugs in an intellectual disability clinical service: retrospective case-note study. J Intellect Disabil 2010;14:237-43.
4. Heslop P, Blair PS, Fleming P, Hoghton M, Marriott A, Russ L. The confidential inquiry into premature deaths of people with intellectual disabilities in the UK: A population-based study. Lancet 2014;383:889-95.
5. Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intellect Disabil Res 2011;55:665-74.
6. Ahmed Z, Fraser W, Kerr MP, Kiernan C, Emerson E, Robertson J, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 2000;176:42-6. (Pubitemid 30051087)
7. Van den Borre R, Vermote R, Buttiens M, et al. Risperidone as add-on therapy in behavioral disturbances in mental-retardation - A double-blind placebo-controlled cross-over study. Acta Psychiat Scand 1993;87:167-71. (Pubitemid 23079926)
8. Gagiano C, Read S, Thorpe L, Eerdekens M, Van Hove I. Short- And long- Term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacology (Berlin) 2005;179:629-36. (Pubitemid 40674764)
9. Campbell M, Robertson A, Jahoda A. Psychological therapies for people with intellectual disabilities: comments on a matrix of evidence for interventions in challenging behaviour. J Intellect Disabil Res 2014;58:172-88.
10. Willner P, Rose J, Jahoda A, Kroese BS, Felce D, Cohen D, et al. Group-based cognitive-behavioural anger management for people with mild to moderate intellectual disabilities: cluster randomised controlled trial. Br J Psychiatry 2013;203:288-96.
11. Tyrer P, Oliver- Africano P, Romeo R, Knapp M, Dickens S, Bouras N, et al. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities (NACHBID); randomised controlled trial. Health Technol Ass 2009;13:iii-iv, ix-xi, 1-54.
12. Oliver- Africano P, Dickens S, Ahmed Z, Bouras N, Cooray S, Deb S, et al. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. J Intellect Disabil Res 2010;54:17-25.